中国麻风皮肤病杂志 ›› 2026, Vol. 42 ›› Issue (3): 163-167.doi: 10.12144/zgmfskin202603163

• 论著 • 上一篇    下一篇

托法替布联合308 nm准分子激光治疗白癜风临床疗效及安全性分析

霍建丽,张少光,王柳   

  1. 保定市第二中心医院，河北保定，072700
  • 出版日期:2026-03-15 发布日期:2026-03-09

Efficacy and safety analysis of tofacitinib combined with 308 nm excimer laser in the treatment of vitiligo

HUO Jianli, ZHANG Shaoguang, WANG Liu   

  1. Department of Dermatology, Baoding Second Central Hospital, Baoding 072700, China
  • Online:2026-03-15 Published:2026-03-09

PDF (PC)

5

摘要： 目的：评价托法替布联合308 nm准分子激光治疗白癜风的疗效及安全性。方法：收集本院诊治的白癜风患者，按照简单排序随机化法分成激光组（308 nm准分子激光治疗）和研究组（在激光组基础上加用托法替布治疗），比较2组疗效、皮损面积、皮肤病学生活质量指数（DLQI）评分、血清免疫球蛋白（Ig）水平、炎性反应指标（ICAM-1）和（IL-17）水平及安全性。结果：预测收集样本量至少83例，本研究实际收集患者90例（2022年5月至2024年7月）,去除剔除及中途退出病例后，最终激光组42例和研究组43例纳入研究。研究组总有效率较激光组高（90.70% vs. 73.81%，P＜0.05）。研究组患者DLQI评分、血清IgA、IgG、ICAM-1和IL-17水平下降程度较激光组明显，差异有统计学意义（均P＜0.05）。研究组不良反应发生率和激光组比较差异无统计学意义（16.28% vs.9.52%，P＞0.05）。结论：对白癜风患者应用托法替布可提高308 nm准分子激光治疗的效果，有效调节免疫功能及炎性反应，且安全性高。

关键词: 托法替布, 308 nm准分子激光, 白癜风

Abstract: Objective: To evaluate the clinical efficacy and safety of tofacitinib combined with 308 nm excimer laser in the treatment of vitiligo. Methods: Patients with vitiligo diagnosed and treated in our hospital were enrolled and randomly assigned to the laser group (treated with 308 nm excimer laser monotherapy) and the study group (treated with tofacitinib plus 308 nm excimer laser) using a simple sequential randomization method. The two groups were compared in terms of clinical efficacy, lesion area, Dermatology Life Quality Index (DLQI) scores, serum immunoglobulin (Ig) levels, inflammatory markers of intercellular adhesion molecule 1 (ICAM-1) and interleukin 17 (IL-17), as well as safety profiles. Results: A minimum sample size of 83 cases was estimated for this study. A total of 90 patients were recruited from May 2022 to July 2024. After excluding cases that were withdrawn or lost to follow-up, 42 patients in the laser group and 43 patients in the study group were finally included in the statistical analysis. The overall response rate was significantly higher in the study group than in the laser group (90.70% vs. 73.81%, P＜0.05). Compared with the laser group, the study group showed more significant reductions in DLQI scores and serum levels of IgA, IgG, ICAM-1 and IL-17, with statistically significant differences (Ps＜0.05). There was no significant difference in the incidence of adverse reactions between the study group and the laser group (16.28% vs. 9.52%, P＞0.05). Conclusion: The addition of tofacitinib to 308 nm excimer laser therapy can enhance the therapeutic effect in vitiligo patients, effectively regulate immune function and inflammatory responses, with a favorable safety profile.

Key words: tofacitinib, 308 nm excimer laser, vitiligo